Literature DB >> 26113680

Tuberculosis associates with both airflow obstruction and low lung function: BOLD results.

André F S Amaral1, Sonia Coton2, Bernet Kato2, Wan C Tan3, Michael Studnicka4, Christer Janson5, Thorarinn Gislason6, David Mannino7, Eric D Bateman8, Sonia Buist9, Peter G J Burney10.   

Abstract

In small studies and cases series, a history of tuberculosis has been associated with both airflow obstruction, which is characteristic of chronic obstructive pulmonary disease, and restrictive patterns on spirometry. The objective of the present study was to assess the association between a history of tuberculosis and airflow obstruction and spirometric abnormalities in adults.The study was performed in adults, aged 40 years and above, who took part in the multicentre, cross-sectional, general population-based Burden of Obstructive Lung Disease study, and had provided acceptable post-bronchodilator spirometry measurements and information on a history of tuberculosis. The associations between a history of tuberculosis and airflow obstruction and spirometric restriction were assessed within each participating centre, and estimates combined using meta-analysis. These estimates were stratified by high- and low/middle-income countries, according to gross national income.A self-reported history of tuberculosis was associated with airflow obstruction (adjusted odds ratio 2.51, 95% CI 1.83-3.42) and spirometric restriction (adjusted odds ratio 2.13, 95% CI 1.42-3.19).A history of tuberculosis was associated with both airflow obstruction and spirometric restriction, and should be considered as a potentially important cause of obstructive disease and low lung function, particularly where tuberculosis is common.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26113680      PMCID: PMC4594762          DOI: 10.1183/13993003.02325-2014

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  28 in total

1.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

Review 2.  The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design.

Authors:  A Sonia Buist; William M Vollmer; Sean D Sullivan; Kevin B Weiss; Todd A Lee; Ana M B Menezes; Robert O Crapo; Robert L Jensen; Peter G J Burney
Journal:  COPD       Date:  2005-06       Impact factor: 2.409

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Pulmonary impairment after tuberculosis.

Authors:  Jotam G Pasipanodya; Thaddeus L Miller; Mauricio Vecino; Guadalupe Munguia; Robert Garmon; Sejong Bae; Gerry Drewyer; Stephen E Weis
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

Review 5.  Thoracic sequelae and complications of tuberculosis.

Authors:  H Y Kim; K S Song; J M Goo; J S Lee; K S Lee; T H Lim
Journal:  Radiographics       Date:  2001 Jul-Aug       Impact factor: 5.333

6.  Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction.

Authors:  M P Swanney; G Ruppel; P L Enright; O F Pedersen; R O Crapo; M R Miller; R L Jensen; E Falaschetti; J P Schouten; J L Hankinson; J Stocks; P H Quanjer
Journal:  Thorax       Date:  2008-09-11       Impact factor: 9.139

Review 7.  Chronic inactive pulmonary tuberculosis and treatment sequelae: chest radiographic features.

Authors:  A Hicks; S Muthukumarasamy; D Maxwell; D Howlett
Journal:  Int J Tuberc Lung Dis       Date:  2014-02       Impact factor: 2.373

8.  Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults.

Authors:  Roberto de Marco; Simone Accordini; Alessandro Marcon; Isa Cerveri; Josep M Antó; Thorarinn Gislason; Joachim Heinrich; Christer Janson; Deborah Jarvis; Nino Kuenzli; Bénédicte Leynaert; Jordi Sunyer; Cecilie Svanes; Matthias Wjst; Peter Burney
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

9.  COPD in never smokers: results from the population-based burden of obstructive lung disease study.

Authors:  Bernd Lamprecht; Mary Ann McBurnie; William M Vollmer; Gunnar Gudmundsson; Tobias Welte; Ewa Nizankowska-Mogilnicka; Michael Studnicka; Eric Bateman; Josep M Anto; Peter Burney; David M Mannino; Sonia A Buist
Journal:  Chest       Date:  2010-09-30       Impact factor: 9.410

10.  Personal and societal health quality lost to tuberculosis.

Authors:  Thaddeus L Miller; Scott J N McNabb; Peter Hilsenrath; Jotam Pasipanodya; Stephen E Weis
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

View more
  56 in total

1.  Chronic lung disease in adult recurrent tuberculosis survivors in Zimbabwe: a cohort study.

Authors:  A T Chin; J Rylance; S Makumbirofa; S Meffert; T Vu; J Clayton; P Mason; P Woodruff; J Metcalfe
Journal:  Int J Tuberc Lung Dis       Date:  2019-02-01       Impact factor: 2.373

Review 2.  Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis.

Authors:  Robert L Hunter
Journal:  Tuberculosis (Edinb)       Date:  2016-01-02       Impact factor: 3.131

Review 3.  Management of chronic obstructive pulmonary disease-A position statement of the South African Thoracic Society: 2019 update.

Authors:  Mohamed Sabeer Abdool-Gaffar; Gregory Calligaro; Michelle Lianne Wong; Clifford Smith; Umesh Gangaram Lalloo; Coenraad Frederik Nicolaas Koegelenberg; Keertan Dheda; Brian William Allwood; Akhter Goolam-Mahomed; Richard Nellis van Zyl-Smit
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

4.  HIV Infection, Pulmonary Tuberculosis, and COPD in Rural Uganda: A Cross-Sectional Study.

Authors:  Crystal M North; Joseph G Allen; Samson Okello; Ruth Sentongo; Bernard Kakuhikire; Edward T Ryan; Alexander C Tsai; David C Christiani; Mark J Siedner
Journal:  Lung       Date:  2017-12-19       Impact factor: 2.584

5.  Chronic respiratory disease in adults treated for tuberculosis in Khartoum, Sudan.

Authors:  R K Osman; K Mortimer; G Bjune; A I El Sony
Journal:  Public Health Action       Date:  2016-09-21

6.  Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study.

Authors:  Jamilah Meghji; Maia Lesosky; Elizabeth Joekes; Peter Banda; Jamie Rylance; Stephen Gordon; Joseph Jacob; Harmien Zonderland; Peter MacPherson; Elizabeth L Corbett; Kevin Mortimer; Stephen Bertel Squire
Journal:  Thorax       Date:  2020-02-26       Impact factor: 9.139

7.  Lung Function and Respiratory Symptoms after Tuberculosis in an American Indian Population. The Strong Heart Study.

Authors:  Martha Powers; Tiffany R Sanchez; Thomas K Welty; Shelley A Cole; Elizabeth C Oelsner; Fawn Yeh; Joanne Turner; Marcia O'Leary; Robert H Brown; Max O'Donnell; David Lederer; Ana Navas-Acien
Journal:  Ann Am Thorac Soc       Date:  2020-01

8.  Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study.

Authors:  Emily S Wan; Spyridon Fortis; Elizabeth A Regan; John Hokanson; MeiLan K Han; Richard Casaburi; Barry J Make; James D Crapo; Dawn L DeMeo; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2018-12-01       Impact factor: 30.528

9.  Doxycycline host-directed therapy in human pulmonary tuberculosis.

Authors:  Qing Hao Miow; Andres F Vallejo; Yu Wang; Jia Mei Hong; Chen Bai; Felicia Sw Teo; Alvin Dy Wang; Hong Rong Loh; Tuan Zea Tan; Ying Ding; Hoi Wah She; Suay Hong Gan; Nicholas I Paton; Josephine Lum; Alicia Tay; Cynthia Be Chee; Paul A Tambyah; Marta E Polak; Yee Tang Wang; Amit Singhal; Paul T Elkington; Jon S Friedland; Catherine Wm Ong
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

Review 10.  Platelet Activation and the Immune Response to Tuberculosis.

Authors:  Daniela E Kirwan; Deborah L W Chong; Jon S Friedland
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.